(R)-4-Methyloxazolidin-2-one → (R)-3-{3-(3-acetyl-2-oxoimidazolidin-1-yl)-4-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-4-methyloxazolidin-2-one

HRID 1804289

Reaktionsgleichung

Reaktionsgleichung von HRID 1804289
[C:1]([N:4]1[CH2:8][CH2:7][N:6]([C:9]2[CH:14]=[C:13](Cl)[CH:12]=[CH:11][C:10]=2[C:16]([N:18]2[CH2:23][CH2:22][N:21]([C:24]3[C:29]([CH3:30])=[CH:28][C:27]([CH3:31])=[CH:26][N:25]=3)[CH2:20][CH2:19]2)=[O:17])[C:5]1=[O:32])(=[O:3])[CH3:2].[CH3:33][C@@H:34]1[CH2:38][O:37][C:36](=[O:39])[NH:35]1>>[C:1]([N:4]1[CH2:8][CH2:7][N:6]([C:9]2[CH:14]=[C:13]([N:35]3[C@H:34]([CH3:33])[CH2:38][O:37][C:36]3=[O:39])[CH:12]=[CH:11][C:10]=2[C:16]([N:18]2[CH2:23][CH2:22][N:21]([C:24]3[C:29]([CH3:30])=[CH:28][C:27]([CH3:31])=[CH:26][N:25]=3)[CH2:20][CH2:19]2)=[O:17])[C:5]1=[O:32])(=[O:3])[CH3:2]

Komponenten

3

Versuchsvorschrift

By reaction and treatment in the same manner as in Example 201 and using 1-acetyl-3-{5-chloro-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}imidazolidin-2-one (519 mg) described in Preparation Example 126 and (R)-4-methyloxazolidin-2-one (115 mg) described in Preparation Example 25, the title compound (69.9 mg) was obtained.

Aufarbeitung

  1. customBy reaction and treatment in the same manner as in Example 201
  2. customdescribed in Preparation Example 25

Quellen und Nachweise

ORD-Eintrag
ord-f6aaf0ea394b4710977984fb5cf055f2
Quelldatensatz
uspto-grants-2013_01
Patentnummer
US08354401B2

Verknüpfte Notizen

Wird geladen…